Please login to the form below

Not currently logged in
Email:
Password:

Santarus adds two board members

Alessandro Della Chà and Dr Matthew Strobeck join US biopharma

Santarus has appointed Alessandro Della Chà and Dr Matthew Strobeck to its board of directors.

The appointments mean the US-based biopharma firm, which has products including Glumetza (metformin hydrochloride extended release tablets) and Cycloset (bromocriptine mesylate) tablets, has now increased its number of directors to nine.

“We welcome our new board members and look forward to drawing on their industry, business and corporate expertise as we continue to build Santarus into a premier specialty biopharmaceutical company,” said David Hale, chair of Santarus.

Della Chà has been a senior partner of Italian commercial law firm Studio Legale Edoardo Ricci e Associati, since 1997. He has also been co-managing director of the company since 2003. He currently also serves as a director of Cosmo Pharmaceuticals.

Dr Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management from 2008 to 2011. He currently serves as a member of the board of directors of Metabolix.

11th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...